Abstract: A saw assembly including a base, a frame assembly disposed on the base and a rail system disposed on the frame assembly. The rail system extends in a longitudinal direction and a table assembly is slidingly disposed in the longitudinal direction on the rail system. The assembly includes a split table having a first table portion and a second table portion separated by a gap extending parallel to the longitudinal direction of the rail system. A pair of fences are mounted to the first and second table portions and bridge the gap to connect the first and second table portions to each other. The gap and corresponding channels and drain apertures allow the tile saw to channel and retain water while cutting a tile. At least one of the fences has a projection in the form of a bridge that is pivotable about the fence to move the projection away from the path of the blade.

Abstract: A system for limiting a peak current of short-circuit current comprises a first high-frequency branch configured to provide a first high-frequency current to a first switch (1SKa) of a first phase branch of a three-phase AC when the first phase branch occurs a short-circuit; a second high-frequency branch configured to provide a second high-frequency current to a second switch (1SKc) of a second phase branch of the three-phase AC when the second phase branch occurs a short-circuit; and a third phase branch of the three-phase AC connected in parallel with the first phase branch and the second phase branch and configured to always supply power.

Abstract: The present invention discloses a system for limiting a peak current of short-circuit current, which comprises a first a first high-frequency branch configured to provide a first high-frequency current to a first switch (1SKa) of a first phase branch of a three-phase AC when the first phase branch occurs a short-circuit, wherein the first high-frequency current is configured to cause a zero-crossing point of a short-circuit current to appear before a zero-crossing point of the three-phase AC; a second high-frequency branch configured to provide a second high-frequency current to a second switch (1SKc) of a second phase branch of the three-phase AC when the second phase branch occurs a short-circuit, wherein the second high-frequency current is configured to cause a zero-crossing point of a short-circuit current to appear before a zero-crossing point of the three-phase AC, a third phase branch of the three-phase AC connected in parallel with the first phase branch and the second phase branch and configured to

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: Pharmaceutical compositions comprising poorly soluble compounds, such as BCS class II or class IV drugs (e.g. amuvatinib), are provided. The pharmaceutical compositions are effective for increasing the bioavailability of the compounds. Related kits and methods are also provided.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumors using the formulations are described.

Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Abstract: The present invention provides pharmaceutical formulations of decitabine or 5-aza-2?-deoxycytidine as well as methods of manufacturing the formulations. In particular, decitabine is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering decitabine to treat conditions or diseases, such as cancer and hematological disorders.

Abstract: The present invention provides pharmaceutical formulations of cytidine analogs and derivatives, such as 5-azacytidine, 5-aza-2?-deoxy-2?,2?-difluorocytidine, 5-aza-2?-deoxy-2?-fluorocytidine, 2?-deoxy-2?,2?-difluorocytidine, and cytosine 1-?-D-arabinofuranoside, as well as methods of manufacturing the formulations. In particular, the cytidine analog or derivative is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering the cytidine analog or derivative to treat conditions or diseases, such as cancer and hematological disorders.